02645nam a2200517 i 4500 000710959 StDuBDS 20240202172917.0 20160518115749.0 m||||||||d|||||||| cr ||||||||||| 160408s2016 enka fo 000|0|eng|d NEZPRACOVANÝ IMPORT 9781473973350 (ebook) : No price (OCoLC)1017731210 StDuBDS eng StDuBDS rda pn HD49 658.4056 23 Elias, Jaan, author. Merck and Vioxx. (A), Should the company continue to battle each of the 27,000 lawsuits filed against it? / Jaan Elias, Spencer Hutchins, Andrea Nagy, Constance E. Bagley & Douglas W. Rae. [London] : SAGE, 2016. 1 online resource : illustrations (black and white, and colour). text rdacontent still image rdacontent computer rdamedia online resource rdacarrier SAGE knowledge. Cases Originally Published in: Elias, J., Hutchins, S., Nagy, A., Bagley, C. E., & Rae, D. W. (2008). Merck and Vioxx (A): Should the Company Continue to Battle Each of the 27,000 Lawsuits Filed Against It? 08-016. New Haven, CT: Yale School of Management, Yale University. Over the years, Merck & Co. built an enviable reputation not just as a paragon of the pharmaceutical industry but as one of America's most admired businesses. However, after withdrawing its blockbuster drug Vioxx in September of 2004, Merck found its reputation and its financial stability in danger. The day after the announcement, Merck's stock plunged 30% and a few analysts even wondered if Merck would be forced into bankruptcy. This study looks at the processes that Merck would need to go through before achieving stability. Description based on online resource; title from home page (viewed on May 3, 2016). elektronické knihy fd186907 czenas electronic books eczenas Merck & Co. Crisis management Case studies. Actions and defenses Case studies. Hutchins, Spencer, author. Nagy, Andrea, author. Bagley, Constance E., author. Rae, Douglas W., author. SAGE knowledge. Cases. SAGE knowledge https://sk.sagepub.com/cases/merck-and-vioxx-a-should-the-company-continue-to-battle-the-lawsuits Plný text SBC EB NEPOSILAT EB